Computational screening and molecular docking are two methods that are being used to discover new drugs to combat SARS-CoV-2 infections and COVID-19. Many of these efforts to discover new drugs use SARS-CoV-2 S protein as a pharmacological target. The concept of antimicrobial peptides is to introduce peptides to SARS-CoV-2 S protein that would change the viral protein's conformation so that it cannot properly interact with ACE2 receptors. This would consequently stop the virus from infecting a cell. These synthetic peptides would be more clinically favorable than other antivirals because they have no side effects, cause no hemolytic activity, and are not toxic to human cells. The following peptides were tested by Souza et al.:

• Mo-CBP3-PepI
• Mo-CBP3-PepII
• Mo-CBP3-PepIII [22,23]
• RcAlb-PepI
• RcAlb-PepII
• RcAlb-PepIII [24]
• PepGAT
• PepKAA